Ceramide remodeling in MASLD: linking lipid-fate reprogramming to organelle stress, inflammation, and fibrosis
Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, insulin resistance, and metabolic overload, but hepatic fat accumulation alone does not explain its heterogeneous progression to steatohepatitis, fibrosis, and cirrhosis. Ceramide denotes a bioactive sphingolipid class whose members are generated through de novo synthesis, sphingomyelin hydrolysis, and salvage/recycling pathways. Its biological effects depend on molecular species, metabolic flux, cellular source, and subcellular localization as well as abundance. Human evidence, however, remains heterogeneous and predominantly cross-sectional: no reproducible ceramide-specific signature has been established across the reviewed cohorts and clinical endpoints, and circulating concentrations cannot be assumed to represent hepatocyte or organelle-specific pools. Associations therefore do not establish whether altered ceramide profiles reflect drivers, consequences, or biomarkers of metabolic dysfunction. We use ceramide remodeling as a conceptual umbrella whose individual dimensions require distinct experimental measurements, rather than as a single standardized biological state. Integrating species-resolved lipidomics with source-specific perturbation studies, we propose a context-dependent framework linking lipid-fate reprogramming to organelle stress and inflammatory–fibrotic amplification. Direct mechanistic and therapeutic evidence remains largely preclinical, whereas human findings are interpreted separately by sample compartment, study design, endpoint, and validation status. Limited longitudinal observations support further prognostic investigation but require independent replication. This framework organizes testable hypotheses for spatially resolved causal studies and interventions with empirically defined therapeutic windows; neither clinical utility nor the superiority of selective over broadly distributed treatment has been established.
Authors
- Lin Qi (ORCID: https://orcid.org/0000-0001-7398-327X)
- Yang Du (ORCID: https://orcid.org/0009-0004-8834-8446)
- Xiaoyang Hu (ORCID: https://orcid.org/0000-0001-7329-9697)
- Bojia Li
- Yunze Shi
- Mingfeng Liu
- Xingyuan Huang
- Boqi Ren
Institutions
- Heilongjiang University of Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-11-13
- DOI
- https://doi.org/10.3389/fmed.2026.1972800
- Primary Topic
- Sphingolipid Metabolism and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Heilongjiang Province